1. Home
  2. WFF vs CINGW Comparison

WFF vs CINGW Comparison

Compare WFF & CINGW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WFF
  • CINGW
  • Stock Information
  • Founded
  • WFF 1984
  • CINGW N/A
  • Country
  • WFF Malaysia
  • CINGW United States
  • Employees
  • WFF N/A
  • CINGW 13
  • Industry
  • WFF Miscellaneous manufacturing industries
  • CINGW Biotechnology: Pharmaceutical Preparations
  • Sector
  • WFF Consumer Discretionary
  • CINGW Health Care
  • Exchange
  • WFF Nasdaq
  • CINGW Nasdaq
  • Market Cap
  • WFF N/A
  • CINGW N/A
  • IPO Year
  • WFF 2025
  • CINGW 2021
  • Fundamental
  • Price
  • WFF $3.39
  • CINGW $0.06
  • Analyst Decision
  • WFF
  • CINGW
  • Analyst Count
  • WFF 0
  • CINGW 0
  • Target Price
  • WFF N/A
  • CINGW N/A
  • AVG Volume (30 Days)
  • WFF 860.2K
  • CINGW N/A
  • Earning Date
  • WFF 01-01-0001
  • CINGW N/A
  • Dividend Yield
  • WFF N/A
  • CINGW N/A
  • EPS Growth
  • WFF N/A
  • CINGW N/A
  • EPS
  • WFF 0.02
  • CINGW N/A
  • Revenue
  • WFF $5,656,489.00
  • CINGW N/A
  • Revenue This Year
  • WFF N/A
  • CINGW N/A
  • Revenue Next Year
  • WFF N/A
  • CINGW N/A
  • P/E Ratio
  • WFF $181.40
  • CINGW N/A
  • Revenue Growth
  • WFF N/A
  • CINGW N/A
  • 52 Week Low
  • WFF $3.31
  • CINGW N/A
  • 52 Week High
  • WFF $5.52
  • CINGW N/A
  • Technical
  • Relative Strength Index (RSI)
  • WFF N/A
  • CINGW N/A
  • Support Level
  • WFF N/A
  • CINGW N/A
  • Resistance Level
  • WFF N/A
  • CINGW N/A
  • Average True Range (ATR)
  • WFF 0.00
  • CINGW 0.00
  • MACD
  • WFF 0.00
  • CINGW 0.00
  • Stochastic Oscillator
  • WFF 0.00
  • CINGW 0.00

About CINGW Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Share on Social Networks: